Singular Genomics Systems, which is developing novel next generation sequencing and multiomics technologies, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Singular has developed a unique and proprietary next generation sequencing (NGS) technology, which it refers to as its Sequencing Engine. The company is currently developing two integrated solutions that are purpose built to target specific applications. Its first integrated solution is targeted at the NGS market and comprises its G4 Instrument, a benchtop next generation sequencer, and an associated menu of consumable kits, addressing specific applications in markets including oncology and immune profiling. The company anticipates initiating an early access program followed by a commercial launch of the G4 Integrated Solution by the end of 2021, with intentions for units to ship in the 1H22. Its second integrated solution in development comprises its PX Instrument and an associated menu of consumable kits, which combines single cell analysis, spatial analysis, genomics, and proteomics. The company anticipates commercial launch of the PX Integrated Solution in 2023.
The La Jolla, CA-based company was founded in 2016 and plans to list on the Nasdaq under the symbol OMIC. Singular Genomics Systems filed confidentially on March 22, 2021. J.P. Morgan, Goldman Sachs, BofA Securities, Cowen and UBS Investment Bank are the joint bookrunners on the deal. No pricing terms were disclosed.
